These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 24586868

  • 1. Early growth inhibition is followed by increased metastatic disease with vitamin D (calcitriol) treatment in the TRAMP model of prostate cancer.
    Ajibade AA, Kirk JS, Karasik E, Gillard B, Moser MT, Johnson CS, Trump DL, Foster BA.
    PLoS One; 2014; 9(2):e89555. PubMed ID: 24586868
    [Abstract] [Full Text] [Related]

  • 2. Characterization of Vitamin D insensitive prostate cancer cells.
    Alagbala AA, Moser MT, Johnson CS, Trump DL, Foster BA.
    J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):712-6. PubMed ID: 17280828
    [Abstract] [Full Text] [Related]

  • 3. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
    Wikström P, Lindahl C, Bergh A.
    Prostate; 2005 Feb 01; 62(2):148-64. PubMed ID: 15389804
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.
    Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, Binderup L.
    Cancer Epidemiol Biomarkers Prev; 1999 Mar 01; 8(3):241-8. PubMed ID: 10090302
    [Abstract] [Full Text] [Related]

  • 5. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model.
    Raina K, Rajamanickam S, Singh RP, Deep G, Chittezhath M, Agarwal R.
    Cancer Res; 2008 Aug 15; 68(16):6822-30. PubMed ID: 18701508
    [Abstract] [Full Text] [Related]

  • 6. Androgen-independent prostate cancer progression in the TRAMP model.
    Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM.
    Cancer Res; 1997 Nov 01; 57(21):4687-91. PubMed ID: 9354422
    [Abstract] [Full Text] [Related]

  • 7. Antitumor effects of two less-calcemic vitamin D analogs (Paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells.
    Alagbala AA, Johnson CS, Trump DL, Posner GH, Foster BA.
    Oncology; 2006 Nov 01; 70(6):483-92. PubMed ID: 17237623
    [Abstract] [Full Text] [Related]

  • 8. Dietary tomato and lycopene impact androgen signaling- and carcinogenesis-related gene expression during early TRAMP prostate carcinogenesis.
    Wan L, Tan HL, Thomas-Ahner JM, Pearl DK, Erdman JW, Moran NE, Clinton SK.
    Cancer Prev Res (Phila); 2014 Dec 01; 7(12):1228-39. PubMed ID: 25315431
    [Abstract] [Full Text] [Related]

  • 9. Vitamin D deficiency aggravates growth and metastasis of prostate cancer through promoting EMT in two β-catenin-related mechanisms.
    Zhang ZH, Liu MD, Yao K, Xu S, Yu DX, Xie DD, Xu DX.
    J Nutr Biochem; 2023 Jan 01; 111():109177. PubMed ID: 36223833
    [Abstract] [Full Text] [Related]

  • 10. E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse.
    Wechter WJ, Leipold DD, Murray ED, Quiggle D, McCracken JD, Barrios RS, Greenberg NM.
    Cancer Res; 2000 Apr 15; 60(8):2203-8. PubMed ID: 10786685
    [Abstract] [Full Text] [Related]

  • 11. Safety and chemopreventive effect of Polyphenon E in preventing early and metastatic progression of prostate cancer in TRAMP mice.
    Kim SJ, Amankwah E, Connors S, Park HY, Rincon M, Cornnell H, Chornokur G, Hashim AI, Choi J, Tsai YY, Engelman RW, Kumar N, Park JY.
    Cancer Prev Res (Phila); 2014 Apr 15; 7(4):435-44. PubMed ID: 24501325
    [Abstract] [Full Text] [Related]

  • 12. Vitamin D in Prostate Cancer.
    Ahn J, Park S, Zuniga B, Bera A, Song CS, Chatterjee B.
    Vitam Horm; 2016 Apr 15; 100():321-55. PubMed ID: 26827958
    [Abstract] [Full Text] [Related]

  • 13. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system.
    Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin Z, Day RS, Trump DL, Johnson CS.
    Urology; 1997 Dec 15; 50(6):999-1006. PubMed ID: 9426741
    [Abstract] [Full Text] [Related]

  • 14. Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide.
    Morel KL, Ormsby RJ, Solly EL, Tran LNK, Sweeney CJ, Klebe S, Cordes N, Sykes PJ.
    Clin Exp Metastasis; 2018 Oct 15; 35(7):649-661. PubMed ID: 29936575
    [Abstract] [Full Text] [Related]

  • 15. Immunization against luteinizing hormone-releasing hormone fusion proteins does not decrease prostate cancer in the transgenic adenocarcinoma mouse prostate model.
    Hill RE, de Avila DM, Bertrand KP, Greenberg NM, Reeves JJ.
    Exp Biol Med (Maywood); 2003 Jul 15; 228(7):818-22. PubMed ID: 12876301
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.
    Chen TC, Holick MF, Lokeshwar BL, Burnstein KL, Schwartz GG.
    Recent Results Cancer Res; 2003 Jul 15; 164():273-88. PubMed ID: 12899529
    [Abstract] [Full Text] [Related]

  • 17. Tumor suppressor microRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue.
    Giangreco AA, Vaishnav A, Wagner D, Finelli A, Fleshner N, Van der Kwast T, Vieth R, Nonn L.
    Cancer Prev Res (Phila); 2013 May 15; 6(5):483-94. PubMed ID: 23503652
    [Abstract] [Full Text] [Related]

  • 18. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice.
    Singh RP, Raina K, Sharma G, Agarwal R.
    Clin Cancer Res; 2008 Dec 01; 14(23):7773-80. PubMed ID: 19047104
    [Abstract] [Full Text] [Related]

  • 19. Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.
    Mauri G, Jachetti E, Comuzzi B, Dugo M, Arioli I, Miotti S, Sangaletti S, Di Carlo E, Tripodo C, Colombo MP.
    Oncotarget; 2016 Jan 26; 7(4):3905-20. PubMed ID: 26700622
    [Abstract] [Full Text] [Related]

  • 20. Raf kinase inhibitor protein (RKIP) deficiency decreases latency of tumorigenesis and increases metastasis in a murine genetic model of prostate cancer.
    Escara-Wilke J, Keller JM, Ignatoski KM, Dai J, Shelley G, Mizokami A, Zhang J, Yeung ML, Yeung KC, Keller ET.
    Prostate; 2015 Feb 15; 75(3):292-302. PubMed ID: 25327941
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.